Feng Xian-jun, Department of Respiratory Medicine, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
Qin Xiu-guang, Department of Thoracic Surgery, The First Affiliated Hospital of Xinxiang Medical University, Weihui, China.
Pak J Med Sci. 2014 May;30(3):488-92. doi: 10.12669/pjms.303.4187.
We conducted a perspective study to investigate the association between mRNA expression quantities of ERCC1, BRCA1, RRM1 and RRM2 and response to chemotherapy and clinical outcome of advance Non-Small Cell Lung Cancer.(NSCLC).
Two hundred eight patients who were diagnosed as advanced stage NSCLC were included in our study. A fluorescence-based and real-time detection method was used to determine the relative cDNA quantification for ERCC1, BRCA1, RRM1 and RRM2, and β-actin was used as the reference gene.
The median expression levels of ERCC1, BRCA1, RRM1 and RRM2 mRNA were 0.67±0.17, 0.095±0.012, 0.24±0.17 and 2.45±0.32, respectively. Our study found that the low ERCC1 (OR=1.82, 95% CI=1.01-3.20) and Low BRCA1 (OR=2.53, 95%CI=1.38-4.64) mRNA expression was more likely to response to chemotherapy when compared with high expression, respectively. Multivariate Cox regression analysis indicated that patients with low mRNA expression of ERCC1 and BRCA1 attained 0.43 (OR=0.43, 95%CI=0.27-0.89) and 0.37 (OR=0.37, 95%CI=0.22-0.66) fold risk of death from NSCLC. However, we found RMM1 and RRM2 mRNA expression could not influence the response to chemotherapy and clinical outcome of NSCLC.
ERCC1 and BRCA1 mRNA expression could be important predictive markers for individualized platinum-based chemotherapy for NSCLC patients.
我们进行了一项前瞻性研究，旨在探讨 ERCC1、BRCA1、RRM1 和 RRM2 的 mRNA 表达水平与晚期非小细胞肺癌（NSCLC）患者对化疗的反应和临床结局之间的关系。
本研究纳入了 208 例诊断为晚期 NSCLC 的患者。采用荧光实时定量检测方法检测 ERCC1、BRCA1、RRM1 和 RRM2 的相对 cDNA 定量，以 β-actin 作为内参基因。
ERCC1、BRCA1、RRM1 和 RRM2 mRNA 的中位表达水平分别为 0.67±0.17、0.095±0.012、0.24±0.17 和 2.45±0.32。本研究发现，与高表达相比，低表达 ERCC1（OR=1.82，95%CI=1.01-3.20）和低表达 BRCA1（OR=2.53，95%CI=1.38-4.64）的患者更有可能对化疗产生反应。多因素 Cox 回归分析表明，ERCC1 和 BRCA1 mRNA 低表达的患者 NSCLC 死亡风险分别降低 0.43 倍（OR=0.43，95%CI=0.27-0.89）和 0.37 倍（OR=0.37，95%CI=0.22-0.66）。然而，我们发现 RMM1 和 RRM2 mRNA 表达不能影响 NSCLC 患者对化疗的反应和临床结局。
ERCC1 和 BRCA1 mRNA 表达可以作为 NSCLC 患者个体化铂类化疗的重要预测标志物。
